Aminopeptidase N (APN)/CD13 inhibitor, Ubenimex, enhances radiation sensitivity in human cervical cancer by Tsukamoto, Hirohisa et al.
BioMed  Central
Page 1 of 8
(page number not for citation purposes)
BMC Cancer
Open Access Research article
Aminopeptidase N (APN)/CD13 inhibitor, Ubenimex, enhances 
radiation sensitivity in human cervical cancer
Hirohisa Tsukamoto, Kiyosumi Shibata*, Hiroaki Kajiyama, Mikio Terauchi, 
Akihiro Nawa and Fumitaka Kikkawa
Address: Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Japan
Email: Hirohisa Tsukamoto - tukamoto@med.nagoya-u.ac.jp; Kiyosumi Shibata* - shiba@med.nagoya-u.ac.jp; 
Hiroaki Kajiyama - kajiyama@med.nagoya-u.ac.jp; Mikio Terauchi - mikio727@med.nagoya-u.ac.jp; Akihiro Nawa - nawa2005@med.nagoya-
u.ac.jp; Fumitaka Kikkawa - kikkawaf@med.nagoya-u.ac.jp
* Corresponding author    
Abstract
Background: Radiotherapy can be used to treat all stages of cervical cancer. For improving local
control via radiotherapy, it is important to use additional antitumor agents. Aminopeptidase N
(APN)/CD13, a 150-kDa metalloproteinase, is a multifunctional cell surface aminopeptidase with
ubiquitous expression. Recent studies have suggested that APN/CD13 plays an important role in
tumor progression in several human malignancies.
Methods: We investigated whether the suppression of APN/CD13 using Ubenimex, an inhibitor
of APN/CD13 activity, may affect tumor radiosensitivity in cervical cancer cells both in vitro and in
vivo. Cell surface APN/CD13 activity in HeLa cells was calculated using alanine-p-nitroanilido as a
substrate. For colony formation assays, single-dose radiation and/or Ubenimex were administered
to each dish of HeLa cells, and these dishes were cultured for 14 days. Molecular changes of
apoptosis were determined by Western blot. Apoptosis was evaluated by Annexin-V PI staining
(flow cytometry analysis) and the Tunel method. Moreover, we investigated the effect of combining
Ubenimex and low-dose radiation on tumor growth using nude mice.
Results: We demonstrated that Ubenimex enhanced the effectiveness of radiotherapy, acting as a
radiosensitizer both in vitro and in vivo. In colony formation assays, a significant decline in clonogenic
survival was observed in Ubenimex-treated cells. Mice treated with a combination of radiation and
Ubenimex showed a significant prolongation of the tumor-doubling time compared with the
control, Ubenimex, or radiation-alone groups. We also showed that ubenimex enhanced radiation-
induced apoptosis in vitro and in vivo.
Conclusion: Although further studies are needed, this report suggests that Ubeniemx acts as a
radiosensitizer in cervical cancer treatment, and that the inhibition of APN/CD13 activity may
represent a new approach for improving the therapeutic efficacy of radiotherapy for uterine
cervical cancer.
Published: 19 March 2008
BMC Cancer 2008, 8:74 doi:10.1186/1471-2407-8-74
Received: 15 September 2007
Accepted: 19 March 2008
This article is available from: http://www.biomedcentral.com/1471-2407/8/74
© 2008 Tsukamoto et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Cancer 2008, 8:74 http://www.biomedcentral.com/1471-2407/8/74
Page 2 of 8
(page number not for citation purposes)
Background
Uterine cervical cancer is still the second most common
cancer in women worldwide, despite the existence of
effective screening methods [1]. Radiation therapy can be
used to treat all stages of cervical cancer. Many cervical
cancers are very radiosensitive, and radiotherapy gives
good results; however, residual disease causes clinical
relapse. Thus, for improving the local control of cervical
cancer, the combination of radiation with additional anti-
tumor agents is warranted. Against this background, con-
current chemoradiation with a cisplatin-based regimen
has recently been used to treat advanced cervical cancer
[2-6]. However, the treatment causes strong side effects
such as digestive symptoms (vomiting and diarrhea) and
bone marrow suppression. Thus, drugs with fewer side
effects and a superior effect in combination are desired.
Aminopeptidase N (APN)/CD13 is a zinc-binding type 2
transmembrane ectopeptidase of 150 kDa that forms a
noncovalently bound homodimer on the cellular mem-
brane. Although APN/CD13 was first described as a
marker for hematopoietic cells of myeloid origin, expres-
sion has been reported on non-hematopoietic cells and
tissues, such as fibroblasts, brain cells, and epithelial cells
of the liver, kidney, and intestine. High expression levels
of APN/CD13 have been detected in various solid tumors
[7-9]. The expression level of APN/CD13 was found to
correlate with increased malignant behavior in prostate,
colon, and non-small cell lung cancer [10-12]. Ubenimex,
a CD13/aminopeptidase N (APN) inhibitor, has been
shown to be cytotoxic to tumor cell lines in vitro, and it
dose-dependently inhibits the growth of lung cancer and
leukemic cell lines [13,14]. However, the detailed antitu-
mor mechanism of Ubenimex remains unclear.
In the current study, to improve the therapeutic efficacy of
radiotherapy for cervical cancer, we investigated the
potential of Ubenimex to act as a radiosensitizer. Initially,
in vitro studies showed that Ubenimex potentiated radia-
tion-induced cell killing in a clonogenic assay. This
increased cell killing was correlated with the up-regula-
tion of caspase-3 and PARP cleavage, suggesting the acti-
vation of apoptotic signaling pathways.In vivo, the
combination of Ubenimex with cervical cancer irradiation
led to an enhancement of tumor growth inhibition and
increased cancer tissue apoptosis. Our study demon-
strated the potential for the use of Ubenimex to improve
the effectiveness of clinical strategies in cervical cancer
radiotherapy.
Methods
Cell culture
The human uterine cervical cancer cell line (HeLa) was
used. HeLa cells were kindly provided by Dr. Ruey Min
Lee (Huntsman Cancer Institute, Salt Lake, UT, USA).
Cells were maintained in RPMI-1640 (Sigma, St. Louis,
MO, USA) supplemented with 10% FCS and penicillin-
streptomycin. These cells were incubated at 37°C in a
humidified atmosphere of 5% CO2.
Irradiation
The cells were irradiated at doses between 2 and 14 Gy at
room temperature using an MBR-1505R2 X-ray generator
(Hitachi Medical Co.) delivering 0.8 Gy/min.
Enzyme activity assay
Cell surface APN/CD13 activity in HeLa cells was detected
spectrophotometrically, as reported by Amoscato et al.
[15]. After incubating 4 × 105 cells in a 60 × 15 mm culture
dish for 24 h at 37°C, each dish was irradiated with doses
of 16 Gy. Twelve hours following, aspirating off the
medium and washing with PBS, 1 mM alanine-p-nitroani-
lido (Peptide Institute, Inc.) was added to each dish as a
substrate. Each dish was then incubated at 37°C for 60
min. The supernatant was subsequently collected, and
200 μl of the solution was added to 96-well microtiter
plates. APN/CD13 enzyme activity was measured by a
microplate reader (Tecan; λexc of 405 nm and λem 495 nm)
(Labsystems, Multiskan Bichromatic, Helsinki, Finland).
Clonogenic survival
For colony formation assays, cells (from 100 to 1 × 105
cells) in a 60 × 15 mm culture dish were seeded in tripli-
APN/CD13 enzyme activity in HeLa cells with or without  (control) of radiation (16 Gy) Figure 1
APN/CD13 enzyme activity in HeLa cells with or 
without (control) of radiation (16 Gy). Enzyme activity 
was determined by quantitating the enzymatic cleavage of the 
synthetic substrate alanine-p-nitroanilido. After 1 hour incu-
bation, APN/CD13 activity is depicted as about two fold 
increase in HeLa cells after radiation. Radiation increased 
APN/CD13 enzyme activity. Errors bar represent the stand-
ard error of the mean.BMC Cancer 2008, 8:74 http://www.biomedcentral.com/1471-2407/8/74
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cate according to treatment conditions and cell lines. After
allowing cells to attach to the dishes, a single dose of radi-
ation and/or Ubenimex was given. Cells were always pre-
treated with Ubenimex for 24 h before radiation when the
two treatments were combined. Cells were cultured for up
to 14 days. Colonies were then fixed, stained with crystal
violet, and counted. The surviving fraction was estimated
as follows: (number of colonies formed)/(number of cells
seeded) × [plating efficiency for the no-treatment or Ube-
nimex group (control group)].
Western blot analysis
Cells were grown to 70–80% subconfluence and treated
with lysis buffer containing 1% Triton ×-100 in PBS and
protease inhibitor mixture tablets (Roche, Barcelona,
Spain). Ten μg of total cell lysate were electrophoresed on
a 10% SDS-polyacrylamide gel and transferred electro-
phoretically to Immobilon membranes (Millipore, Bed-
ford, MA, USA). After adding blocking solution (5%
nonfat dry milk/0.1% Tween-20/PBS), the membranes
were incubated overnight with a recommended dilution
of primary antibodies. We used anti-Bcl-xL (Cell Signaling
BD, 2760), anti-Bcl-2 (Cell Signaling BD, 2872), anti-cas-
pase-3 (Santa Cruz, sc-7272), anti-cleaved caspase-3 (Cell
Signaling, 7190), anti-PARP (Cell Signaling, 9542), anti-
cleaved PARP (Cell Signaling, 9541), and anti-β-actin
antibodies (Sigma, AC-74). The primary antibodies were
washed in 0.05% Tween-20/PBS and then incubated with
horseradish peroxidase-conjugated secondary antibody.
Proteins were visualized using enhanced chemilumines-
cence reagent (Amersham Pharmacia Biotech) followed
by exposure to X-ray film.
Flow cytometric analysis for apoptosis
To quantify the apoptotic death of HeLa cells, annexin V
and PI (propidium iodide) staining was performed, fol-
lowed by flow cytometry. Cells were plated at 4 × 105 cells
in a 60 × 15 mm culture dish for 24 h, and treated with 16
Gy irradiation. After treatment for 72 h, attached cells
were collected by brief trypsinization, washed twice with
PBS, and then subjected to annexin V and PI staining
using a MEBCYTO apoptosis kit (MBL). After staining,
quantitative analysis for apoptosis was performed by flow
cytometry.
Tumor model and treatment conditions
Female nude mice (BALB/c) at 6 weeks were provided
from Chubu Kagaku (Nagoya, Japan). HeLa cells (1 × 107
cells/0.5 ml of medium/mouse) were injected into the left
flank of animals. Before initiating the study, 20 mice were
assigned to four groups.
Each group contained an equal number of large and inter-
mediate-sized tumors, and mice were stratified into
groups so that the mean tumor volume in each group was
comparable.
(a) Control group (no radiation, sterile PBS injections),
(b) Radiation alone group (locally radiated at a dose of 4
Gy, sterile PBS injections),
(c) Ubenimex alone group (treatment with Ubenimex for
7 days at 10 mg/kg/day), and
(d) Combination treatment group (concomitant radia-
tion plus Ubenimex for 7 days at 10 mg/kg/day schedul-
ing: started 24 hours before 4 Gy radiation).
For radiation treatment, mice were immobilized in a cus-
tomized harness facilitating exposure of the left flank,
whereas the remainder of the body was shielded by lead.
4 Gy radiation was delivered locally in one fraction on day
7 using an MBR-1505R2 X-ray generator (Hitachi Medical
Co.) delivering 0.8 Gy/min.
Intratumoral injections of Ubenimex began 24 h before
radiation and were continued daily for 7 days. The tumor
volume was estimated from two-dimensional tumor
measurements by the formula: V = length (mm) × width2
(mm2)/2.
The unpaired Student's t-test was used to determine the
significance of the relative tumor volumes and for com-
parisons between groups.
Clonogenic survival of HeLa cells with or without 100 μg/ml  Ubenimex Figure 2
Clonogenic survival of HeLa cells with or without 100 
μg/ml Ubenimex. Colonies were counted 14 days after 
radiation. Errors bar represent the standard error of the 
mean.BMC Cancer 2008, 8:74 http://www.biomedcentral.com/1471-2407/8/74
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TUNEL assay
The TUNEL assay was carried out using MEBSTAIN Apop-
tosis KitII(MBL CO., LTD., Nagoya, Japan). DNA fragmen-
tation was detected by this assay. Paraffin-embedded
sections (4 μm thick) of mice were cut and mounted on
precoated glass slides. Sections were deparaffinized prior
to digestion with 20 μg/mL proteinase K for 15 min at
room temperature. The slides were washed 4 times in dis-
tilled water for 2 min and covered with 2% hydrogen per-
oxide in phosphate-buffered saline (PBS) for 5 min at
room temperature to inactivate endogenous peroxidase.
The slides were rinsed with PBS twice and immersed in
TdT-containing buffer (30 mmol/L Triazma base, pH 7.2,
140 mmol/L sodium cacodylate, and 1 mmol/L cobalt
chloride) for 15 minutes to prepare digoxigenin-binding
sites. An antidigoxigenin antibody fragment carried a con-
jugated reporter enzyme (peroxidase) to the reaction sites,
and then localized peroxidase generated an intense signal
from the chromogenic substrate diaminobenzidine. The
counterstain was made by methyl green. Apoptosis was
defined as the number of stained positive cells under a
200 × fluorescence microscope.
Statistical analysis
Data were obtained from three individual experiments
performed in triplicate. Statistical analysis was performed
using the unpaired Student's t-test. Differences were con-
sidered significant at p < 0.05.
(A)Annexin V and PI (propidium iodide) staining was performed, followed by flow cytometry Figure 3
(A)Annexin V and PI (propidium iodide) staining was performed, followed by flow cytometry. (B) The percentage 
of apoptotic cells was counted (Fig. 3A, areas 2 and 3). Almost 3–4% apoptosis was found in the control and Ubenimex groups. 
In the radiation and combined-treatment groups there was a high percentage of apoptosis. Combined treatment with Uben-
imex and radiation resulted in a higher percentage of apoptosis than in the radiation alone group (p < 0.05). Errors bar repre-
sent the standard error of the mean.BMC Cancer 2008, 8:74 http://www.biomedcentral.com/1471-2407/8/74
Page 5 of 8
(page number not for citation purposes)
Results
Radiation increased APN/CD13 enzyme activity in uterine 
cervical cancer cell line
We first investigated whether radiation increased the cell
surface APN/CD13 activity of HeLa cells. APN/CD13
enzyme activity in HeLa cells with or without of irradia-
tion (16 Gy) was investigated. Enzyme activity was deter-
mined by quantitating the enzymatic cleavage of the
synthetic substrate alanine-p-nitroanilido. After a1-h
incubation, APN/CD13 activity is depicted as about two
fold increase in HeLa cells after radiation (Fig. 1).
Increased HeLa cell killing by Ubenimex and radiation
As radiation increased APN/CD13 activity, we investi-
gated the potential of Ubenimex to act as a radiosensitizer.
HeLa cells were pretreated with 100 μg/ml Ubenimex for
24 h, irradiated with 2–14 Gy, and then plated in a 14-day
clonogenic assay. The survival curves obtained for radia-
tion alone and Ubenimex-treated cells in combination
with irradiation are shown in Fig. 2. A significant decline
in clonogenic survival was observed in Ubenimex treated
cells in combination with radiation of 14 Gy (p < 0.05).
Ubenimex enhanced irradiation-induced apoptosis
To investigate whether the induction of apoptosis plays a
role in Ubenimex-induced radiosensitization, annexin V
and PI (propidium iodide) staining by flow cytometry was
performed (Fig. 3A and 3B). The level of apoptosis was
analyzed at 72 h after 16 Gy radiation, because, at this
time point, the highest level of apoptosis was noted. The
percentage of apoptotic cells was counted (Fig. 3A, areas 2
and 3). Almost 3–4% apoptosis was found in the control
and Ubeninex-alone groups. However, in the 16 Gy radi-
ation-alone and combined-treatment groups, there was a
high percentage of apoptosis. Further, combined treat-
ment with Ubenimex and radiation resulted in a higher
percentage of apoptosis than in the 16 Gy radiation-alone
group. A significant difference was observed between only
radiation and combined treatment with Ubenimex and
radiation (p < 0.05).
Activation of apoptotic pathway by combination of 
Ubenimex and radiation
We investigated the effect of Ubenimex on the modula-
tion of molecules involved in the apoptotic pathway. The
expression of molecules related to apoptosis was deter-
mined by Western blot analysis. As shown in Fig. 4A, the
combination of Ubenimex and radiation enhanced the
expression of cleaved caspase-3 and PARP, leading to
apoptosis. Also, anti-apoptotic molecules, Bcl-xL and Bcl-
2, were down-regulated by Ubenimex and radiation (Fig.
4B). These results showed that the combination of Uben-
imex and radiation activated the apoptotic pathway more
strongly than the other treatments.
Effect of combination of Ubenimex and low-dose radiation 
on tumor growth in vivo
The effect of combined treatment with Ubenimex and
radiation on the growth of HeLa tumors was tested in four
separate experiments. As can be seen in Fig. 5A, mice that
received combined treatment of 4 Gy radiation and Ube-
nimex exhibited much smaller tumors compared with
mice that received no treatment or were treated with only
radiation or Ubenimex. In terms of the tumor volume
doubling time, the Ubenimex-alone group showed no dif-
ference compared with the no-treatment group (2.4 versus
2.5 days, respectively). In contrast, the combined-treat-
ment group showed a significantly longer doubling time
than that of the radiation alone group (17.8 days versus
11.5 days, respectively). As shown in Fig. 5B, to the eye,
tumor appearance in the combined-treatment group was
different from the tumors of the other groups. Regarding
tumor volume, optimal growth inhibition was observed
in the combination treatment group compared with the
radiation alone group (p  < 0.05; combined-treatment
group versus ionizing irradiation) (Fig. 5C). Finally, we
used the TUNEL method to visualize DNA fragmentation
at the single cell level. As shown in Fig. 5D, more apop-
totic cells were observed in the tumor xenografts of the
combined-treatment group than in the other groups.
Modulation of apoptotic molecules by Ubenimex and radia- tion Figure 4
Modulation of apoptotic molecules by Ubenimex and 
radiation. HeLa cells were pretreated with 100 μg/ml Ube-
nimex for 24 h, followed by 16 Gy radiation. At 72 h after 
radiation treatment, whole-cell protein extracts were pre-
pare and subjected to Western blot analysis of Bcl-xL, Bcl-2, 
caspase-3, cleaved caspase-3, PARP, and cleaved PARP. The 
β-actin protein level served as a protein loading control. The 
combination of Ubenimex and radiation cleaved caspase-3 
and PARP, leading to apoptosis (A). Anti-apoptotic mole-
cules, Bcl-xlL and Bcl-2, were down-regulated by Ubenimex 
and radiation (B).BMC Cancer 2008, 8:74 http://www.biomedcentral.com/1471-2407/8/74
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Discussion
In the current study, we first focused on Ubenimex as a
drug used in combination with radiation in cervical can-
cer treatment. The combined antitumor activity of radia-
tion and Ubenimex was tested both in vitro and in vivo. In
our animal model, treatment with Ubenimex alone did
not influence tumor growth in nude mice inoculated s.c.
with HeLa cells. However, combined treatment with Ube-
nimex and radiation resulted in a significantly higher
response rate compared with radiation alone. These
results are consistent with in vitro data shown in Figs. 2
and 3. In this study, the combined treatment was mark-
edly effective in vivo, but not in vitro. This is presumably
because we used relatively large numbers of cells in in-
vitro assays. In addition, our apoptosis assay results
include those of assays for late apoptosis and necrosis,
and so further studies using low-dose radiation are
needed. The mechanism by which APN/CD13 activity
functions in the regulation of radiosensitivity remains to
be clarified. APN/CD13 has been suggested to be involved
in the degradation of neuropeptides, cytokines, and
immunomodulatory peptides, as well as angiotensins
[16,17]. Thus, it is possible that APN/CD13 activity may
contribute to radioresistance through proteolytically
modifying peptides involved in anti-apoptotic signaling.
Ubenimex inhibits APN/CD13, aminopeptidase B, and
leucine aminopeptidase of mammalian cells [18]. An
antigrowth or antimigratory effect is frequently observed
(A) Effect of Ubenimex alone or combined with radiation on s.c Figure 5
(A) Effect of Ubenimex alone or combined with radiation on s.c. HeLa tumor volumes (mm3) over time (days). Mice 
were treated with PBS, bestatin, 4 Gy+PBS, and 4 Gy+bestatin, and tumor volumes were monitored over time. Mice were sac-
rificed on 23rd day. (B) Photographs of tumors on the 23rd day. (C) Tumor weight on the 23rd day. Optimal growth inhibition 
was observed in the 4 Gy+bestatin group compared with the other groups. (D)TUNEL assay of mouse tumor sections. This 
method allows the direct detection of DNA fragmentation. The bright cells are apoptotic cells. More apoptotic cells were 
observed in the combined-treatment group than in the other groups. Errors bar represent the standard error of the mean.BMC Cancer 2008, 8:74 http://www.biomedcentral.com/1471-2407/8/74
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in studies using Ubenimex or anticatalytic antibodies for
APN/CD13 in several malignancies [19-23]. Our results
show that Ubenimex acted as a radiosensitizer to enhance
radiation-induced apoptosis in cervical cancer cells. This
finding suggests that the concomitant use of Ubenimex
during radiotherapy could be a potential therapeutic
approach to improve the efficacy of radiotherapy for uter-
ine cervical cancer.
The mechanism involved in the combined treatment of
Ubenimex and radiation remains unknown; the two
agents achieve cytotoxicity through different means. Pre-
vious studies have shown that Ubenimex directly induces
the apoptosis of human leukemia and non-small-lung
cancer cells [13,14]. Furthermore, previous studies have
shown that Ubenimex enhances apoptosis or increases
sensitivity to antineoplastic agents [24-27]. Consistent
with these findings, the present data suggested that Uben-
imex enhanced the radiosensitivity of cervical cancer. In
this study, we speculated that Ubenimex would induce
apoptosis by inhibiting the radiation-induced activity of
APN/CD13. However, no significant apoptosis induction
was observed after the expression of APN/CD13 was
knocked out by siRNA (data not shown). One of possible
explanation for this observation is that Ubenimex may
inhibit other aminopeptidase activities, and thereby influ-
ence the cell cycle or apoptotic signals, since it is not com-
pletely specific for APN/CD13. Santos et al. demonstrated
that APN/CD13 was directly involved in signal transduc-
tion pathways, including the phosphorylation of
mitogen-activated protein kinases, such as ERK1/2, JNK,
and p38, in monocytes [28]. Although the detailed mech-
anisms are still under investigation, APN/CD13 may be
involved in signaling cascades regulating cell survival,
protection from apoptosis, and radiosensitivity via ami-
nopeptidase-dependent and independent mechanisms.
This study may be controversial in that 50 times the clini-
cal dose of Ubenimex was administered. Ubenimex is an
immunomodulator with few side effects, but may cause
mild nausea, vomiting, and liver dysfunction. In addition,
further studies are needed to investigate the methods of
Ubenimex administration. In conclusion, the data
obtained here suggested that APN/CD13 activity was
induced with radiation, and the inhibition of APN/CD13
may lead to the restoration of radiosensitivity in cervical
cancer cells. Although there are always limitations when
one attempts to extrapolate from mice to humans, our
study suggests that combination with ubenimex may pro-
vide additional benefits regarding the radiosensitivity of
cervical cancer.
Conclusion
This work demonstrated that inhibition of APN/CD13
activity may represent a new approach for improving the
therapeutic efficacy of radiotherapy for uterine cervical
cancer.
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